歌禮(01672.HK)午後挫22% 內地醫保名單三種丙肝藥降價八成
內地公布醫保藥品名單,新增70個藥品平均降價60.7%,其中三種丙肝治療用藥降幅平均更超過85%,腫瘤及糖尿病等治療藥物平均降價約65%。
相關股今天以目前只有兩款分別治療丙肝「戈諾衛」及乙肝「派羅欣」藥物上市的歌禮製藥-B(01672.HK)表現最差,股價午後跌幅由半日市不足一成,擴至最多急挫22.6%,一舉失守四條移動平均(50天及百天線分別為3.63元及4.05元),最低見3.53元,現造3.54元,急挫22%,成交急增至1,844萬股,涉資7,276萬元。
有研發腫瘤藥的綠葉製藥(02186.HK)曾失守100天、250天及50天線(6.03-6.08元),最低見5.89元,現造6.05元,續跌3.5%,成交倍增至2,842萬股,涉資1.71億元。不過,金斯瑞生物(01548.HK)逆市反覆回升3.2%報19.58元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.